Fabry disease registry and pregnancy follow-up
Part of Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study collects health information from people with Fabry disease and specifically from pregnant people with Fabry disease. It helps researchers better understand the condition and how pregnancy affects health, using information you already experience in routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Fabry disease
- You can show proof of low alpha-galactosidase enzyme activity and/or a related gene change
- You sign the informed consent and authorization forms
- For the pregnancy part: you are pregnant now or have been pregnant
- For the pregnancy part: you are (or will be) enrolled in the Fabry Registry before pregnancy data is collected
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with Fabry disease who are taking or planning to take the medication Elfabrio (pegunigalsidase alfa). It will look at how safe and effective the treatment is in real-world use.
This trial tests if the oral drug migalastat is safe and works for children aged 2 to under 12 with a specific type of Fabry disease. It may be an option if your child has not been on enzyme therapy recently and has a compatible gene variant.
This study looks at how well available Fabry disease treatments (like migalastat or ERT) work over time in real life. It may help doctors understand who benefits most from these medicines.
This study is a national registry that collects health and medical information from people with Fabry disease. It helps researchers better understand the condition and plan future care and studies.
This study follows pregnant and breastfeeding women with Fabry disease (and their infants) to better understand what happens during pregnancy and early life. You may or may not be taking migalastat, and the goal is to gather real-world information that could help future care.
This study is creating a registry of people with Fabry disease to better understand how it affects the heart. By joining, you help doctors learn more about the condition and improve care for future patients.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.